MK-677 (Ibutamoren) and Levothyroxine Interaction

Why This Interaction Matters

Growth hormone (GH) and thyroid hormones share overlapping regulatory pathways in the hypothalamic-pituitary axis. MK-677 (ibutamoren) is an oral ghrelin receptor agonist that raises GH and IGF-1 levels for up to 24 hours per dose. A two-month trial in healthy older adults (N=65) demonstrated that ibutamoren 25 mg daily increased IGF-1 by approximately 40% without tachyphylaxis over the study period [1]. That sustained GH elevation directly affects how the body handles thyroid hormones.

Levothyroxine (Synthroid, Euthyrox, Tirosint) is the standard replacement for hypothyroidism and carries a narrow therapeutic index. The FDA-approved prescribing information explicitly warns that drugs affecting thyroid hormone synthesis, secretion, distribution, metabolism, or action may alter levothyroxine requirements [2]. GH-raising compounds fall into several of those categories simultaneously.

For the estimated 12% of the U.S. population with some degree of thyroid dysfunction [3], adding a GH secretagogue without monitoring can push a previously stable TSH out of range. The interaction is not rare or theoretical. It is predictable from known physiology.

The Pharmacodynamic Mechanism

The primary interaction between ibutamoren and levothyroxine is pharmacodynamic, not pharmacokinetic. No shared CYP450 enzymes or P-glycoprotein transport competition has been documented between these two compounds.

GH excess increases the activity of type 1 and type 2 iodothyronine deiodinases, which convert T4 (the storage form) to T3 (the active form) in peripheral tissues [4]. In a patient taking exogenous T4 only (levothyroxine), faster peripheral conversion depletes the circulating T4 pool. The pituitary detects lower free T4 and responds by increasing TSH output, but in a patient whose thyroid cannot respond (because it is replaced by exogenous levothyroxine), TSH simply rises without a compensatory increase in endogenous T4 production.

A second mechanism involves somatostatin. Elevated GH feeds back to increase hypothalamic somatostatin tone. Somatostatin inhibits TSH secretion directly at the pituitary level [5]. This creates a paradox: the patient may show mildly suppressed TSH in the first 1 to 2 weeks (from somatostatin), followed by a delayed TSH rise over 4 to 8 weeks as T4 depletion accumulates. Clinicians unfamiliar with this biphasic pattern may misinterpret the early suppressed TSH as evidence that no interaction exists.

A 1997 study in GH-deficient adults receiving GH replacement (N=36) found that 36% required an increase in levothyroxine dose within 6 months of starting GH therapy [6]. While ibutamoren raises GH less aggressively than injectable somatropin (typical peak GH of approximately 15 to 20 mcg/L vs. supraphysiologic peaks with injection), the 24-hour pulsatile GH elevation it produces is sufficient to alter thyroid economy in susceptible individuals.

Who Is at Highest Risk

Not every person combining these compounds will need a levothyroxine adjustment. Risk stratification helps identify those who need closer monitoring.

Patients with no residual thyroid function (post-thyroidectomy, post-radioactive iodine ablation) are at highest risk because they rely entirely on exogenous T4 and cannot compensate for accelerated peripheral conversion. A prospective study of GH replacement in adults after pituitary surgery found that 47% of athyreotic patients required levothyroxine dose increases vs. 16% of patients with partial thyroid function [7].

Patients on borderline-adequate levothyroxine doses (TSH 3.0 to 4.5 mIU/L before starting ibutamoren) have less buffer. Even a small increase in T4-to-T3 conversion can push their TSH above the reference range. Older adults are also more sensitive because GH-mediated metabolic shifts interact with age-related declines in thyroid hormone clearance.

Patients with intact thyroid glands who are not on levothyroxine may still experience a subclinical shift in thyroid function on ibutamoren. A study of MK-677 in healthy elderly subjects noted a decrease in serum T4 of 19.6 nmol/L (approximately 1.5 mcg/dL) after two weeks of dosing, though values remained within the normal range for most participants [1]. Healthy thyroids compensated. Replaced thyroids cannot.

Levothyroxine Absorption: A Separate Concern

Levothyroxine absorption is famously sensitive to timing and co-administered substances. The FDA label recommends taking it on an empty stomach, 30 to 60 minutes before breakfast, with water only [2]. Calcium, iron, proton pump inhibitors, coffee, and fiber all reduce absorption by 20% to 40% in published studies [8].

MK-677 is typically taken at bedtime or in the morning. If a patient takes both compounds simultaneously, there is no documented direct binding or chelation interaction. Ibutamoren does not contain polyvalent cations. Still, the general principle of separating levothyroxine from all other oral compounds by at least 30 to 60 minutes applies here. The conservative approach: take levothyroxine first thing in the morning on an empty stomach, and dose ibutamoren at bedtime.

This separation also helps distinguish absorption-related TSH changes from the pharmacodynamic interaction described above. If a patient's TSH rises after starting ibutamoren and the compounds are already separated by many hours, the clinician can attribute the shift to the GH-thyroid axis interaction rather than an absorption problem.

Monitoring Protocol

The Endocrine Society's 2011 clinical practice guideline on GH replacement in adults recommends checking thyroid function at baseline and every 6 months during GH therapy [9]. For patients on levothyroxine who begin ibutamoren (a non-FDA-approved GH secretagogue producing a milder GH elevation), a reasonable approach adapts that guideline to a tighter initial window.

Baseline (before starting ibutamoren): Check TSH, free T4, and free T3. Document the current levothyroxine dose and whether the patient is athyreotic or has residual function.

Week 6 to 8: Recheck TSH and free T4. If TSH has risen by more than 1.0 mIU/L or is above the upper reference limit, increase levothyroxine by 12.5 to 25 mcg and recheck in another 6 weeks.

Month 3 and every 3 months thereafter: Continue TSH monitoring until two consecutive values are stable on the same levothyroxine dose. After that, routine monitoring every 6 to 12 months is sufficient.

Free T3 measurement at baseline and at week 6 provides an additional signal. If free T3 rises while free T4 falls, this confirms accelerated peripheral deiodination as the mechanism, which helps the clinician rule out other causes of TSH elevation (nonadherence, absorption changes, new medications).

Metabolic Overlap: Glucose and Insulin

Both ibutamoren and thyroid status affect glucose metabolism, creating a second area of pharmacodynamic overlap. MK-677 25 mg daily raised fasting glucose by an average of 0.3 mmol/L (approximately 5 mg/dL) and fasting insulin by 1.4 mIU/L in a year-long trial of older adults (N=65) [10]. GH is a counter-regulatory hormone that opposes insulin action in muscle and liver tissue.

Hypothyroidism, especially when undertreated, also impairs glucose metabolism by reducing hepatic glucose output and slowing insulin clearance. If the GH-thyroid interaction causes a patient to become functionally more hypothyroid (rising TSH, falling free T4), insulin resistance from ibutamoren and insulin resistance from worsening hypothyroidism may compound.

For patients with prediabetes or type 2 diabetes on levothyroxine, this stacking effect warrants monitoring hemoglobin A1c and fasting glucose alongside thyroid function. A rise in A1c of 0.2% to 0.4% within 3 months of starting ibutamoren has been reported anecdotally in GH-deficiency registries using injectable somatropin, and a similar magnitude is plausible with ibutamoren in metabolically vulnerable patients.

What Prescribers Should Know About MK-677's Regulatory Status

MK-677 is not FDA-approved for any indication. It was investigated by Merck in the late 1990s and early 2000s for GH deficiency, sarcopenia, and hip fracture recovery, but it never received marketing authorization. The compound is sold as a "research chemical" and appears in peptide and performance-enhancement supply chains.

The FDA's 2017 warning letter to SARMs distributors included references to GH secretagogues marketed alongside SARMs. Prescribers encountering patients already self-administering ibutamoren should document this in the chart, adjust monitoring accordingly, and counsel on the absence of quality control in unregulated supply.

"Any compound that raises GH levels for a sustained period will affect the thyroid axis. We routinely recheck TSH when starting GH therapy, and the same vigilance applies to oral GH secretagogues like ibutamoren," states the Endocrine Society's 2011 guideline committee position on GH-thyroid monitoring [9].

Dose-Response Considerations

The magnitude of the GH-thyroid interaction correlates with the degree of IGF-1 elevation. In dose-ranging studies, MK-677 at 10 mg daily raised IGF-1 by approximately 30%, while 25 mg daily raised IGF-1 by approximately 40% to 60% [1]. The lower dose would be expected to produce a smaller thyroid perturbation, though no trial has directly compared thyroid outcomes across ibutamoren doses.

Patients who have been on a stable 25 mg dose and reduce to 10 mg may experience a fall in GH/IGF-1 that shifts thyroid balance in the opposite direction. A levothyroxine dose that was increased during 25 mg ibutamoren use might become excessive at the lower ibutamoren dose, causing iatrogenic thyrotoxicosis. Dose changes in either compound should trigger TSH monitoring at 6 to 8 weeks.

"When GH therapy is discontinued, patients may need their levothyroxine reduced to avoid overreplacement," notes the AACE 2019 clinical practice guidelines for GH use in adults [11]. The same principle applies when ibutamoren is stopped.

Practical Patient Counseling Points

Clinicians managing patients who disclose ibutamoren use alongside levothyroxine should cover these specific points:

Timing: take levothyroxine on waking, 30 to 60 minutes before any food or supplement. Take ibutamoren at bedtime to maximize the natural nocturnal GH pulse and avoid any theoretical absorption overlap.

Symptom awareness: fatigue, cold intolerance, constipation, and weight gain after starting ibutamoren may signal worsening hypothyroidism rather than side effects of ibutamoren itself. These symptoms should prompt an early TSH check rather than waiting for a scheduled visit.

Lab timing: draw TSH and free T4 before the morning levothyroxine dose (trough level). Draw fasting glucose and insulin in the morning, fasted, at least 8 hours after the last ibutamoren dose.

Discontinuation: if stopping ibutamoren, recheck TSH in 6 to 8 weeks. The levothyroxine dose may need to be reduced to pre-ibutamoren levels to avoid overreplacement symptoms (palpitations, tremor, anxiety, bone loss with prolonged excess).

Other Drug Interactions with MK-677

Beyond levothyroxine, ibutamoren has pharmacodynamic interactions with several drug classes. Glucocorticoids (prednisone, dexamethasone) blunt GH secretion and may partially offset ibutamoren's effect while compounding its glucose-raising action [12]. Dopamine agonists (cabergoline, bromocriptine) suppress GH and could reduce ibutamoren efficacy. Insulin and sulfonylureas may require dose adjustment given ibutamoren's insulin-antagonizing effect.

No significant CYP3A4 inhibition or induction has been documented for ibutamoren at standard doses. The compound is primarily metabolized by CYP3A4, so strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) could theoretically increase ibutamoren exposure, though clinical data quantifying this effect are not available [1].

Patients on multiple interacting medications should have a comprehensive review before adding an unapproved GH secretagogue. The absence of an FDA-approved label for ibutamoren means no formal drug interaction studies with standard DDI methodology have been completed, and all interaction data are extrapolated from GH physiology, small trials, and case reports.

Checking TSH 6 to 8 weeks after any change in ibutamoren dose or discontinuation remains the single most actionable monitoring step for patients on concurrent levothyroxine therapy.